Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer

Published:2015-02 Issue:3 Volume:51 Page:317-326
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Novello Silvia,Kaiser Rolf,Mellemgaard Anders,Douillard Jean-Yves,Orlov Sergey,Krzakowski Maciej,von Pawel Joachim,Gottfried Maya,Bondarenko Igor,Liao Meilin,Barrueco José,Gaschler-Markefski Birgit,Griebsch Ingolf,Palmer Michael,Reck Martin

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Non-small Cell Lung Cancer, version 2. In; 2014.

2. The evolving role of histology in the management of advanced non-small-cell lung cancer;Langer;J Clin Oncol,2010

3. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies;Li;J Clin Oncol,2013

4. Pfizer Inc., Xalkori (crizotinib) prescribing information. In; 2013.

5. AstraZeneca Ltd., Iressa (gefitinib) Summary of Product Characteristics. In; 2013.

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Les CBNPC de stades avancés hors addiction oncogénique : les traitements systémiques de deuxième ligne;Revue des Maladies Respiratoires Actualités;2023-10

2. Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity;Frontiers in Oncology;2023-08-10

3. New advances in the research of clinical treatment and novel anticancer agents in tumor angiogenesis;Biomedicine & Pharmacotherapy;2023-07

4. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Annals of Oncology;2023-04

5. Impact of new cancer medicine – real-world evidence from Danish register study of lung cancer patients;Acta Oncologica;2023-03-04